Capacity to enjoy longer life
The annotation by Bittles and Glasson 1 confirms trends noted worldwide of improved life expectancy not only for people with Down syndrome but also for those with other disabilities, including cerebral palsy. Mortality rates in Down syndrome are now improving at a rate greater than those of the general population. The move from institutional to community care in developed countries has been met with an improvement in nutrition, lower infection risk and, with life holding more outside the institutional walls, overwhelmingly, an improvement in spirit.
Arithmetic means are sensitive to outliers and improved mortality rates in early infancy have contributed significantly to the noted trend. The indifference, and at times negative attitudes noted by Silverman 2 in the 1980s, of doctors towards Down syndrome, has largely been replaced by a far more positive approach. Survival following cardiac surgery is now as good as that seen in all children. This has an important influence on mortality rates, as up to half of children with Down syndrome have congenital heart disease. A service review has emphasized the need to support and communicate well with families at a time when they are faced not only with disability but with the prospect of major surgery; the review also called for doctors to present a balanced view of treatment options. 3 A major point from the report and subsequent commentary is that life-prolonging treatment is in the interest of people with Down syndrome and that most people with Down syndrome do have a good quality of life, certainly as judged by them. It follows that equality of access to treatment options should be maintained. 4 Improved treatment of leukaemia, which affects 1 per cent of young people with Down syndrome, has also increased life expectancy. Chessels 5 has highlighted how, over the past decade, improved knowledge of how to use chemotherapeutic agents and antimicrobials has enhanced survival. We know that over-expression of cystathionine synthetase is associated with very low levels of atheroma and that solid tumours and multiple sclerosis are seen only very rarely in Down syndrome. One biological disadvantage of Down syndrome is the overactivity of superoxide dismutase, leading to increased intracellular oxidative activity and a process akin to accelerated aging. Great interest is, therefore, currently centred on the possible long-term benefit of antioxidants with the possibility of delaying the onset of Alzheimer's disease, which affects up to 50% of adults with Down syndrome.
Are these scientific advances matched by improvement in medical practice? GK Chesterton said 'I do not know what I think about a thing until I hear what I say'. Increasingly, doctors are talking of 'giving' the news following the birth of a new baby with Down syndrome -which as Bittles and Glasson point out is an increasing occurrence -rather than 'breaking' the news. The implication is that the arrival of a child with a disability is not necessarily a bad thing, there are positive aspects too. Families adjust following the early disappointment and live to laugh again. A doctor's positive attitude, attained through
